4D Molecular Therapeutics (FDMT) Income Statement: Revenue & Earnings

4D Molecular Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

4D Molecular Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.04	20.72	3.13	18.04	13.61
Cost of Revenue	0.00	97.10	80.25	61.36	53.04
Gross Profit	0.04	-76.37	3.13	-43.32	-39.43
Operating Expenses
Research & Development	141.30	97.10	80.25	61.36	0.00
Selling, General & Administrative	46.58	36.49	32.91	28.01	17.24
Operating Expenses	187.88	133.59	113.16	28.01	17.24
Operating Income	-187.84	-112.87	-110.03	-71.33	-56.66
Other Income/Expense
Interest Income	27.05	12.21	2.57	0.14	0.15
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	-0.08	-0.18	-0.04	-0.12	-0.18
Income
Income Before Tax	-160.87	-100.84	-107.49	-71.32	-56.69
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-160.87	-100.84	-107.49	-71.32	-56.69
Net Income - Continuous Operations	-160.87	-100.84	-107.49	-71.32	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-181.14	-107.12	-106.15	-69.81	-55.22
EBIT	-187.84	-112.87	-110.03	-71.33	-56.66
Depreciation & Amortization	6.71	5.75	2.40	1.52	1.44
Earnings Per Share
Basic EPS	-3.00	-3.00	-3.00	-3.00	-9.00
Diluted EPS	-3.00	-3.00	-3.00	-3.00	-9.00
Basic Shares Outstanding	53.94	39.13	32.35	27.73	6.43
Diluted Shares Outstanding	53.94	39.13	32.35	27.73	6.43